Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621141 | 0.80 | MEN1 (0.37) | DPP4F2TSHRTAAR1HTR2A | |
| SCHEMBL16924879 | 0.76 | DPP4 (0.39) | DPP4F2TSHRTAAR1HTR2A | |
| SCHEMBL11782888 | 0.74 | DPP4 (0.38) | DPP4F2TSHRTAAR1HTR2A | |
| SCHEMBL20765676 | 0.74 | CYP2D6 (0.44) | DPP4F2TSHRLMNACYP2D6 | |
| SCHEMBL28845872 | 0.74 | DPP4 (0.38) | DPP4F2TSHRTAAR1HTR2A | |
| SCHEMBL874358 | 0.74 | CYP2D6 (0.44) | DPP4F2TSHRLMNACYP2D6 | |
| SCHEMBL3322544 | 0.74 | TSHR (0.38) | DPP4F2TSHRTAAR1HTR2A | |
| SCHEMBL11783704 | 0.73 | MIF (0.33) | DPP4F2TSHRTAAR1HTR2A | |
| SCHEMBL11783699 | 0.73 | MIF (0.33) | DPP4F2TSHRTAAR1HTR2A | |
| SCHEMBL4660604 | 0.72 | DPP4 (0.41) | DPP4F2TSHRTAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | claimed |
| CN-107337659-A | Compounds as protein kinase modulators | 理森制药股份公司 | 2017-11-10 | — | — | CN | disclosed |
| CN-103702989-B | Novel compounds as modulators of protein kinases | 理森制药股份公司 | 2017-07-07 | — | — | CN | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| EP-1282610-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-6914059-B2 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AG (DE) | 2005-07-05 | — | — | US | disclosed |
| US-20040006075-A1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AG (DE) | 2004-01-08 | — | — | US | disclosed |
| EP-1282610-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001081323-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006075-A1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | CYP4Z1, XDH, CYP3A5 | DPP4 509/4885F2 789/4885TSHR 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.